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Background: Prostate cancer is the most commonly diagnosed non-melanoma cancer among men. Androgen
deprivation therapy (ADT) has been the core therapy for men with advanced prostate cancer. It is only in recent
years that clinicians began to recognize the cognitive-psychosocial side effects from ADT, which significantly
compromise the quality of life of prostate cancer survivors. The objectives of the study are to determine the efficacy
of a simple and accessible home-based, walking exercise program in promoting cognitive and psychosocial
functions of men with prostate cancer receiving ADT.
Methods: A 6-month prospective, single-blinded, randomized controlled trial will be conducted to compare the
Exercise Group with the Control Group. Twenty men with prostate cancer starting ADT will be recruited and
randomly assigned to one of the two groups: the Exercise Group will receive instructions in setting up an
individualized 6-month home-based, walking exercise program, while the Control Group will receive standard
medical advice from the attending physician. The primary outcomes will be psychosocial and cognitive functions.
Cognitive functions including memory, attention, working memory, and executive function will be assessed using a
battery of neurocognitive tests at baseline and 6 months. Psychosocial functions including depression, anxiety and
self-esteem will be assessed at baseline, 3 and 6 months using the Center for Epidemiological Studies Depression
Scale, Spielberger State-Trait Anxiety Inventory, and Rosenberg Self-Esteem Scale.
Discussion: The significance of the cognitive-psychosocial side effects of ADT in men with prostate cancer has only
been recently recognized, and the management remains unclear. This study addresses this issue by designing a
simple and accessible home-based, exercise program that may potentially have significant impact on reducing the
cognitive and psychosocial side effects of ADT, and ultimately improving the health-related quality of life in men
with prostate cancer receiving ADT.
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In North America, prostate cancer is the most commonly
diagnosed non-melanoma skin cancer. It is estimated
that 25,500 men in Canada [1] and over 2.3 million men
in the United States have prostate cancer [2]. More than
one-third of men with prostate cancer will develop recur-
rent disease and receive androgen deprivation therapy
(ADT) [3]. ADT is accomplished by bilateral orchiect-
omy or the use of a luteinizing hormone-releasing hor-
mone agonist. The duration of response to ADT using
hormone agonist ranges from 12 to 18 months, with 20%
of patients having a complete prostate specific antigen
response at 5 years [4]. However, there are a number of
long-term health, cognitive, and psychosocial sequelae
from ADT that significantly impact the health-related
quality of life of men with prostate cancer.
The cognitive-psychosocial side effects of ADT are dis-
tinct health care needs of prostate cancer survivors that
are not recognized until recent years. Studies have
revealed that men receiving ADT have reduced cognitive
function and self-esteem, and increased depression and
anxiety secondary to the therapeutically-induced reduc-
tion of testosterone level [5-12]. Cognitive domains that
are most significantly affected include verbal memory
and learning [6,7], spatial memory and ability [5,8],
visuomotor skills [10], executive function [6], and atten-
tion [7]. Men with prostate cancer receiving ADT are at
a particularly higher risk of developing cognitive and de-
pressive disorders than men without cancer [11]. These
cognitive-psychosocial problems associated with ADT
result in a significant reduction of health-related quality
of life of prostate cancer survivors.
Physical activities through exercise is a lifestyle inter-
vention that has protective effect against the risk of
developing depression and anxiety disorders in the gen-
eral population [13-15], and also improve cognitive func-
tion in older adults [16-18]. Regular exercise improves
cardiovascular fitness, which in turn associates positively
with cognitive performance in older adults and may have
protective effect against cognitive decline later in life
[19-23]. The underlying mechanism of how exercise
improves cognitive and psychosocial functions are not
clear. However, evidence suggests that increases in hip-
pocampal volume [24,25] and brain monoaminergic sys-
tems [26] are possible mediating factors for improved
memory function in individuals with higher cardiovascu-
lar fitness levels. Exercise, therefore, could have a poten-
tially significant impact on improving the mental health
and health-related quality of life of prostate cancer
survivors.
Walking, in particular, is a simple and easily accessible
form of exercise that can be readily incorporated into the
long-term lifestyle of cancer survivors. Walking exercise
has vast benefits on the quality of life and overall healthincluding cognitive function in older adults [27,28]. In
women with breast cancer, walking exercise has shown
to significantly improve their health-related quality of
life, fatigue, physical and mental health, [29-34] and even
overall survival rate [35,36]. In men with prostate cancer
on ADT, studies that investigated the role of exercise
utilized mostly resistance exercise or a combination of
resistance and aerobic trainings [37]. The results demon-
strated that exercise could significantly reduce fatigue,
improve muscular strength, physical function and overall
health-related quality of life in men with prostate cancer.
However, the effect of exercise, specifically walking, in
the cognitive-psychosocial functions of men with pros-
tate cancer on ADT is unknown. Therefore it is impera-
tive to investigate if a simple walking exercise program
will improve cognitive-psychosocial functions of men
with prostate cancer on ADT.
The objective of the study is to determine the efficacy
of a simple and accessible home-based walking exercise
program in promoting cognitive-psychosocial functions
of men with prostate cancer receiving ADT.
Methods
A 6-month prospective, assessor-blinded, randomized
controlled trial will be conducted to compare an Exercise
Group to a Control Group. Patients will be recruited
through CancerCare Manitoba. Baseline and follow-up
visits will be conducted at the Department of Physical
Therapy at the University of Manitoba. The University of
Manitoba Research Ethics Board has approved the study
protocol (Ethics Reference # H2008:318), which is also in
compliance with the Helsinki Declaration.
Participants
Inclusion criteria
Patients will be included in the study if they are men
aged 50 years or older, diagnosed with adenocarcinoma
prostate cancer, and will initiate and receive continuous
ADT (luteinizing hormone releasing hormone agonist
(LHRH) or combination of LHRH and anti-androgen)
for at least 6 months after recruitment. Patients will be
required to provide written informed consent to partici-
pate in the study.
Exclusion criteria
Patients will be excluded from the study if they have
severe cardiac disease (New York Heart Association
class III or greater), angina, pre-existing osteoporosis
with T-score at or below −2.5, stable bone lesion, un-
controlled hypertension (blood pressure > 160/95 mm
Hg), moderate to severe aortic stenosis, acute illness or
fever, uncontrolled atrial or ventricular dysrhythmias,
uncontrolled sinus tachycardia (> 120 beats per mi-
nute), third-degree atrio-ventricular heart block, active
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ism, deep vein thrombosis, uncontrolled diabetes, un-
controlled pain, cognitive impairment, history of falls
due to balance impairment or lost of consciousness, or
severe neuromusculoskeletal conditions that limit their
ability to perform walking exercise (including ataxia,
peripheral or sensory neuropathy, unstable bone lesion,
severe arthritis, pathological lower limb fractures within
6 months, lower limb amputation).
Recruitment
A total of 20 patients will be recruited consecutively dur-
ing office visits at the initial 3-month phase of the study
at CancerCare Manitoba. The attending physician will
screen the patients for inclusion criteria (men aged 50 or
older, diagnosed with adenocarcinoma prostate cancer,
will initiate and receive continuous ADT (LHRH or com-
bination of LHRH and anti-androgen for at least
6 months). The physicians will be provided with an infor-
mation sheet that provides brief information about study.
If the patients meet the preliminary inclusion criteria, the
physicians will provide a brief explanation about the
study, and verbal consent to refer them to a clinical re-
search nurse. The clinical research nurse will confirm that
all inclusion and exclusion criteria are met, explain the
study protocol, provide an information sheet for patients,
and obtain written informed consent from the patients
who would like to participate in the study. The clinical re-
search nurse will provide the student research assistant
(SRA) with the signed consent forms and contact informa-
tion of the consented patients of the study.
Assessment sessions
Each participant will attend a total of three assessment
sessions: one baseline, and two follow-up sessions at 3
and 6 months after ADT initiation at the Department of
Physical Therapy. The Exercise Group will complete
telephone survey between follow-up sessions.
Baseline assessment session
The SRA, who is trained in health sciences field, will
contact the participants to schedule a baseline assess-
ment in coordination with a clinical psychology research
assistant (CPRA), who is trained to administer neuro-
psychological tests.
The baseline assessment will be administered by the
CPRA first, followed by the SRA. The CPRA will collect
the sociodemographic characteristics, and administer the
primary (cognitive-psychosocial functions) and second-
ary outcome measures (health related quality of life
(HRQOL)). The SRA will collect data on the physical ac-
tivity variables.
The CPRA will be blinded to the group assignments of
the participants. After the baseline assessment, the SRAwill assign the participant the first available number
from a randomly generated list consisting of “1” and “2”,
that are generated by mixed randomization, [38] using
both simple randomization and permuted-block meth-
ods. Number “1” is designated as the Exercise Group
that will receive instructions in setting up an individua-
lized 6-month home-based walking exercise program in
addition to their daily activities. Number “2” is desig-
nated as the Control Group that will be advised to per-
form daily activities as usual and follow the standard
medical advice from their attending physician.
Follow-up sessions
The CPRA will schedule follow-up sessions for all parti-
cipants at 3 and 6 months after ADT initiation. At
3 months, primary outcome (psychosocial functions)
and secondary outcome variables (HRQOL) will be re-
assessed. At 6 months, all primary (cognitive and psy-
chosocial functions) and secondary (HRQOL) outcome
measures will be re-assessed.
Control group protocol
The SRA will provide each participant of the Control
Group with a pedometer to monitor his ambulatory ac-
tivities. The participants will also be provided with a
take-home package that includes written instructions,
pedometer daily logs, and self-addressed envelopes. The
participants will be instructed to wear the pedometer
during waking hours, except while bathing, swimming
or any procedures that do not allow metal parts to be
close to targeted treatment area. The pedometer will be
worn on a waistband, at or slightly anterior to the mid-
axillary placement. A 50-step preferred-pace trial walk
will be used to determine the side of pedometer place-
ment. The side that yields the least percentage error in
step counts will be the side for the individual’s daily ap-
plication [39]. At the end of each day, participants will
record the date, total daily time wearing the pedometer,
and the number of daily steps taken, and then reset the
pedometer to zero. Every two weeks, the SRA will call
the participants to check for concerns and remind them
to return their pedometer daily logs using the self-
addressed envelopes.
Exercise group protocol
The SRA will assess the baseline health and fitness of
the participants of the Exercise Group using an exercise
screening form that includes the revised Physical Activ-
ity Readiness Questionnaire (PAR-Q)[40], and other
screening questions for exercise contraindications and
precautions. If any exercise contraindications (e.g. short-
ness of breath, severe headache, sudden onset of numb-
ness or weakness) is present, the participant will be
excluded from the study and referred to their family
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(e.g. fever, severe cachexia, extreme fatigue, sickness or
bone pain) is present, high-intensity or high-impact ex-
ercise will be avoided initially. If severe nausea or painful
calf is present, the participants will be advised to consult
their family physician for further investigation and clear-
ance prior to beginning the exercise program.
The SRA will provide each participant of the Exercise
Group with a pedometer and a take-home package that
contains pedometer and exercise instructions and pre-
cautions, daily logs, general exercise tips, stretching
instructions and self-addressed envelopes. The pedom-
eter instructions and daily log instructions are same as
per Control Group protocol.
The Exercise Group will follow a walking exercise pro-
gram that comprises a progressive structured exercise
protocol and progressive target daily step counts regi-
men. The structured exercise protocol will initially begin
with a 10-minute walking session, 3 sessions per week.
The Exercise Group participants will be instructed to
perform a 5-minute warm-up period by walking slowly,
followed by a 10-minute walking workout period, and
then a 5-minute cool-down period by walking slowly
and a stretching routine that is in the Exercise Group
taken-home package. The SRA will also demonstrate to
the participants how the stretches are to be done.
Participants will use the Borg Scale of Ratings of Per-
ceived Exertion (RPE) [41] to estimate their exercise in-
tensity level during the workout and warm-up/cool-
down periods. RPE is a reliable method in monitoring
and regulating exercise intensity, with high correlation
to oxygen uptake (r ≥ 0.83) [42] and high internal
consistency at different levels of velocities and heart
rates (α > 0.90) [43]. During the warm-up/cool-down
periods, the participants will maintain an exertion level
between 7.5 and 8 on (i.e. extremely light level of exer-
tion). During the 10-minute walking workout session,
the participants will gradually increase their walking
speeds until they attain and maintain an RPE level be-
tween 9 and 13 (i.e. very light to light exertion) accord-
ing to their baseline physical activity level (sedentary,
moderately active, or active) as reported on their self-
reported physical activity questionnaire. Sedentary indi-
viduals will start at RPE level of 9 (very light exertion),
moderately active individuals will start at RPE level of 11
(light exertion), and active individuals will start at RPE
level of 13 (somewhat hard exertion).
Each participant’s exercise level will be progressed
every two week, first in frequency (1-day increment),
then walking session (5-minute increment, and lastly
RPE level. Based on the set progression protocol, the
Exercise Group participants will be performing five
walking exercise sessions per week, 30 minutes walk-
ing workout period per session, and will have attainedRPE level of 15 (heavy exertion) by around 18 to
20 weeks. This level of exercise protocol will be main-
tained for the rest of the study period. The partici-
pants are instructed to record the date, start time,
exercise duration and maximum RPE attained during
each session in an exercise daily log.
The participants will also be encouraged to walk at
their chosen pace at times outside their structured exer-
cise protocol so as to achieve their assigned target daily
step counts. The initial target will be set at 5000 steps
for sedentary individuals, 6000 steps for moderately ac-
tive individuals, and 7000 steps for active individuals.
The target daily step counts will be progressed every two
weeks (1000-steps increment) up to a maximum daily
target of 10,000 steps. The participants will be counseled
on the warning symptoms of impending cardiovascular
events including chest pain or discomfort, shortness of
breath, dizziness, severe headache, sudden onset of
numbness or weakness, or painful calf suggestive of deep
vein thrombosis. They will be strongly advised to discon-
tinue the exercise program and report these symptoms
to their attending physician and SRA immediately.
The SRA will call the Exercise Group participants every
two weeks to monitor their safety, adherence, and progress
using a short, structured phone survey. The results of the
phone survey will be used to guide the adjustments/
progression of the structured exercise and step counts
protocols. In addition, the participants will return their
pedometer and exercise daily logs every four weeks.
Data collection
At baseline session, the CRN will collect clinical data
from the medical records of all consented patients that
will include current cancer stage, time since diagnosis,
treatment intent, testosterone level, prostate specific
antigen level, Gleason score, comorbidity index. The
SRA will collect sociodemographic data including age,
marital status, ethnicity, living arrangement, education,
work status, alcohol consumption and smoking history.
At baseline and 6-month follow-up visits, the primary
outcome variable of cognitive function including mem-
ory, attention and working memory, and executive func-
tion will be assessed by the CPRA using well-established
neurocognitive tests. Additionally, each participant will
complete a standardized “effort test” to ensure validity of
the test results. A minimum of 6 months between tests
is required to prevent practice or carry-over effects.
Memory will be assessed using: (1) the Brief Visuospatial
Memory Test - Revised (BVMT-R)[44] for non-verbal
memory, and (2) the California Verbal Learning Test,
2nd Edition (CVLT-II)[45] for verbal memory. Attention
and working memory will be assessed using: (3) the Digit
Span and Letter-Number Sequencing tasks from the
Wechsler Adult Intelligence Scale – 3rd Edition (WAIS-
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Stroop Color and Word Test[47] for processing speed
and inhibition, and (5) the Trail Making Test Parts A
and B [48] for visuomotor tracking and mental flexibil-
ity. Test-taking effort of the neurocognitive tests will be
confirmed using the (6) Word Memory Test (WMT)
[49].
At baseline and all follow-up sessions (3 and 6 months),
the primary (psychosocial functions) and secondary out-
come variables (HRQOL) will be assessed. Cognitive func-
tion of self-reported memory function will be assessed
using the Prospective Retrospective Memory Question-
naire (PRMQ) [50,51] for short and long-term memory.
Psychosocial function will be assessed using: (8) the Center
for Epidemiological Studies Depression (CES-D) for depres-
sion,[52] (9) the Spielberger State-Trait Anxiety Inventory
(STAI)[53] for anxiety, (10) the Rosenberg Self-Esteem
Scale (SES) for self-esteem.[54,55] HRQOL will be assessed
using (12) the Functional Assessment of Cancer Therapy
Prostate Module (FACT-P)[56] as a disease-specific global
HRQOL instrument. Every four weeks, physical activity
levels of both Control and Exercise groups will be moni-
tored based on the completed pedometer daily logs
returned by all participants.
Exercise group
Exercise adherence of the Exercise Group participants
will be monitored using the exercise daily logs returned
every four weeks, and phone surveys conducted by SRA
every two weeks. The phone surveys will also be used to
monitor exercise safety and progress.
Statistical analysis
Primary outcome variables
A mixed between-within-subjects multivariate analysis
of variance (MANOVA) (Group X Time) will be con-
ducted to determine if there is a significant interaction
between the between-subjects (Group) and within-
subjects (Time) comparisons for:
– cognitive function based on the neurocognitive tests
at baseline and 6-month follow-up session;
– psychosocial function at baseline, 3- and 6-month
follow-up sessions;
Secondary outcome variables
Pearson product–moment correlation will be conducted
to determine the association between HRQOL and pri-
mary outcome variables (cognitive and psychosocial
functions).
For The Exercise Group, Spearman-Rank Or Pearson
Product–Moment Correlations Will Be Performed To
Determine If Baseline Sociodemographic, Clinical, Psy-
chosocial, And Physical Activity Factors Are SignificantlyAssociated With Exercise Adherence (Average Percent-
age Of Adherence To The Target Exercise Frequency,
Duration And Intensity Based On The Exercise And
Pedometer Daily Logs).
Discussion
The significance of the cognitive-psychosocial side effects
of ADT in men with prostate cancer has only been re-
cently recognized, and the management remains unclear.
Exercise through regular physical activity has proven to
have tremendous health benefits in older adults and can-
cer survivors. However, the potential impacts of walking
exercise on the cognitive and psychosocial functions of
men with prostate cancer receiving ADT are unknown.
The study addresses this issue by designing a simple and
accessible home-based walking exercise program to deter-
mine its effect on promoting psychosocial and cognitive
functions of men with prostate cancer receiving ADT.
This study is significant because a successful home-based
exercise program for men with prostate cancer would be
cost-effective, and has a potentially significant impact on
a number of ADT-related comorbidities, including redu-
cing psychosocial and cognitive functional decline. This
multidisciplinary study lays the foundation for the devel-
opment of a prevention and wellness program within a
multidisciplinary, comprehensive cancer care program for
men with prostate cancer.Competing interests
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